9.00
-0.44(-4.66%)
Currency In USD
| Previous Close | 9.44 |
| Open | 9.33 |
| Day High | 9.42 |
| Day Low | 8.86 |
| 52-Week High | 18.9 |
| 52-Week Low | 6.66 |
| Volume | 887,724 |
| Average Volume | 1.74M |
| Market Cap | 889.64M |
| PE | -11.11 |
| EPS | -0.81 |
| Moving Average 50 Days | 10.56 |
| Moving Average 200 Days | 12.37 |
| Change | -0.44 |
If you invested $1000 in ARS Pharmaceuticals, Inc. (SPRY) since IPO date, it would be worth $360 as of February 21, 2026 at a share price of $9. Whereas If you bought $1000 worth of ARS Pharmaceuticals, Inc. (SPRY) shares 5 years ago, it would be worth $175.99 as of February 21, 2026 at a share price of $9.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy® (epinephrine nasal spray) at 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting
GlobeNewswire Inc.
Feb 10, 2026 1:00 PM GMT
-Five poster presentations highlight clinical advancement of neffy, real-world usability and advantages of needle-free epinephrine delivery -Longer shelf life of nasal epinephrine compared with epinephrine auto-injectors translates into a more afford
EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing ≥15 kg to <30 kg
GlobeNewswire Inc.
Feb 02, 2026 1:00 PM GMT
EURneffy 1 mg will be the first and only needle-free adrenaline available to younger children in the European Union ARS Pharma’s partner, ALK-Abelló A/S, who owns the rights to market EURneffy in the EU, will distribute following expected authorizati
California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use
GlobeNewswire Inc.
Jan 21, 2026 1:00 PM GMT
California joins 23 other states eligible to receive free neffy® (epinephrine nasal spray) at schools SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk